The front page of AI-driven biology
Thursday, October 15, 2026Thu, Oct 15
Updated 6:32 PM PT
The B7-H3-directed antibody-drug conjugate risvutatug rezetecan reached a median overall survival of 18.5 months versus 10.3 months for topotecan chemotherapy in a Phase 3 study of relapsed small-cell lung cancer.
Adding the kinase inhibitor zipalertinib to platinum-based chemotherapy extended median progression-free survival to 14.5 months compared to 8.5 months for chemotherapy alone in previously untreated non-small cell lung cancer with EGFR exon 20 insertion mutations.
BioNTech's gotistobart, an antibody targeting the immune checkpoint CTLA-4, reached a median overall survival of 18.5 months versus 10 months for docetaxel chemotherapy in patients with relapsed squamous non-small cell lung cancer.
Definium Therapeutics reported that its single-dose oral LSD formulation, DT120 ODT, met the primary endpoint of the 245-patient Phase 3 Panorama trial in generalized anxiety disorder.
The FDA cleared Scholar Rock's myostatin-inhibiting monoclonal antibody Isembyld, also known as apitegromab, for spinal muscular atrophy in patients aged two and older who take SMN2-targeting therapies.
A combination of Amgen's T-cell engager Imdelltra (tarlatamab) and AstraZeneca's checkpoint inhibitor Imfinzi prolonged overall survival compared to Imfinzi alone in untreated, extensive-stage small-cell lung cancer.
Researchers introduced QuantaMind, a machine-learning force field designed to simulate bond-breaking and bond-forming reactions with density functional theory accuracy.
Researchers introduced Fluxion, a generative deep learning framework that models enzyme catalysis by generating dynamic, multi-step electron-flow pathways across active-site residues.
Computational biologists introduced DNT, a genomic language model framework that represents paired maternal and paternal chromosome sequences together rather than processing isolated haploid genomes.